Cancers 2012, 4(4), 1229-1246; doi:10.3390/cancers4041229
Review

Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response

1,2, 1,2, 1,2 and 1,2,* email
Received: 8 October 2012; in revised form: 9 November 2012 / Accepted: 14 November 2012 / Published: 22 November 2012
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Despite recent advances in cancer immunotherapy, no prospectively validated intermediate biomarkers exist to predict response. These biomarkers are highly desirable given modern immunotherapy’s paradoxical pattern of clinical benefit; that is, improvement in overall survival without short-term change in progression. Immunotherapy clinical trials have evaluated biomarkers that may correlate with clinical outcomes. Many of them are performed on peripheral blood to evaluate the systemic response, such as tumor-targeted humoral and cellular immunity, and cytokine responses. Accumulating evidence suggests that immune infiltrates in tumors may suggest evidence for the therapy’s mechanism of action, and have greater potential for providing prognostic and predictive information. In addition, a non-immunologic biomarker, such as tumor growth kinetics, may explain this paradoxical pattern of clinical benefit, and predict survival in patients treated with an immunotherapy. Prospective assessment and validation of these and other intermediate markers would be required to better understand their potential clinical role.
Keywords: surrogate marker; immune assay; tumor-infiltrating lymphocytes; tumor growth rate
PDF Full-text Download PDF Full-Text [156 KB, uploaded 22 November 2012 09:47 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Kim, J.W.; Bilusic, M.; Heery, C.J.; Madan, R.A. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 2012, 4, 1229-1246.

AMA Style

Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers. 2012; 4(4):1229-1246.

Chicago/Turabian Style

Kim, Joseph W.; Bilusic, Marijo; Heery, Christopher J.; Madan, Ravi A. 2012. "Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response." Cancers 4, no. 4: 1229-1246.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert